

BIOGEN IDEC INC  
Form 3  
October 21, 2005

**FORM 3 UNITED STATES SECURITIES AND EXCHANGE COMMISSION**  
**Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0104  
Expires: January 31, 2005  
Estimated average burden hours per response... 0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,  
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section  
30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person *		2. Date of Event Requiring Statement	3. Issuer Name <b>and</b> Ticker or Trading Symbol	
Â Hamm Robert A		(Month/Day/Year)	BIOGEN IDEC INC [BIIB]	
(Last)	(First)	(Middle)	4. Relationship of Reporting Person(s) to Issuer	5. If Amendment, Date Original Filed(Month/Day/Year)
BIOGEN IDEC INC.,Â 14			(Check all applicable)	
CAMBRIDGE CENTER			<input type="checkbox"/> Director	<input type="checkbox"/> 10% Owner
(Street)			<input checked="" type="checkbox"/> Officer	<input type="checkbox"/> Other
			(give title below)	(specify below)
CAMBRIDGE,Â MAÂ 02142			SVP, Immunology Business Unit	6. Individual or Joint/Group Filing(Check Applicable Line)
(City)	(State)	(Zip)		<input checked="" type="checkbox"/> Form filed by One Reporting Person
				<input type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	9,494.434 <sup>(1)</sup>	D	Â

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)	3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form of Derivative Security: Direct (D)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Title			

Edgar Filing: BIOGEN IDEC INC - Form 3

	Expiration Date	Amount or Number of Shares	or Indirect (I) (Instr. 5)
Stock Option (right-to-buy) <sup>(2)</sup>	12/09/2000 <sup>(3)</sup> 12/09/2009	Common Stock 28,750 \$ 62.28	D Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/15/2001 <sup>(4)</sup> 12/15/2010	Common Stock 5,750 \$ 45.46	D Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/14/2002 <sup>(5)</sup> 12/14/2011	Common Stock 10,062 \$ 49.03	D Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/06/2003 <sup>(6)</sup> 12/06/2012	Common Stock 20,124 \$ 37.45	D Â
Stock Option (right-to-buy) <sup>(2)</sup>	12/31/2004 <sup>(7)</sup> 02/06/2014	Common Stock 27,475 \$ 43.45	D Â
Stock Option (right-to-buy) <sup>(2)</sup>	02/17/2006 <sup>(8)</sup> 02/17/2015	Common Stock 45,000 \$ 67.57	D Â

## Reporting Owners

Reporting Owner Name / Address	Relationships			
	Director	10% Owner	Officer	Other
Hamm Robert A BIOGEN IDEC INC. 14 CAMBRIDGE CENTER CAMBRIDGE, MA 02142	Â	Â	Â SVP, Immunology Business Unit	Â

## Signatures

By: Benjamin S. Harshbarger; For: Robert Hamm 10/21/2005

Signature of Reporting Person

Date

## Explanation of Responses:

- \* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Number of directly held shares consists of 336,434 shares acquired through the Issuer's Employee Stock Purchase Plan and a grant 9158 shares of Restricted Stock which fully vest on 02/06/2007.
- (2) Granted under one of the Issuer's stock option plans, in an exempt transaction under SEC rule 16(b)-3(d).
- (3) The stock option became exercisable in five (5) equal annual installments, commencing one year after the grant date of 12/09/99.
- (4) The stock option becomes exercisable in five (5) equal annual installments, commencing one year after the grant date of 12/15/00.
- (5) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/14/01.
- (6) The stock option became exercisable in four (4) equal annual installments, commencing one year after the grant date of 12/06/02.
- (7) The stock option becomes exercisable in four (4) equal annual installments on 12/31/04, 12/31/05, 12/31/06 and 12/31/07.
- (8) The stock option becomes exercisable in four (4) equal annual installments, commencing one year after the grant date of 02/17/05.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.